Group 1 - The treatment level for lymphoma, particularly Diffuse Large B-cell Lymphoma (DLBCL), has significantly improved over the past 20 years, with a 5-year overall survival rate exceeding 60% [1] - Despite advancements, a considerable number of newly diagnosed DLBCL patients do not achieve complete remission after standard treatment (R-CHOP regimen) and face a high risk of relapse [1] - The development of precision-targeted therapies has diversified treatment options, leading to improved outcomes for previously poorly responding DLBCL patients [1] Group 2 - Traditional efficacy assessment for lymphoma relies on PET-CT imaging, which has limitations such as increased radiation dose and difficulty in distinguishing between active immune cells and tumor lesions [2] - PET-CT assessments are typically conducted only after three and six treatment cycles, hindering early detection of treatment failures [2] - Liquid biopsy technology based on circulating tumor DNA (ctDNA) is being explored for its clinical application, as ctDNA can serve as a molecular marker for tumor burden and treatment response [2] Group 3 - Shanghai Ruian Gene Technology Co., Ltd. has developed a "B-cell lymphoma ctDNA detection kit" with patented probes and algorithms, showing promising research results in collaboration with Ruijin Hospital [3] - The kit allows for the assessment of DLBCL patients' responses to standard treatment after just one treatment cycle, and pre-treatment ctDNA detection can predict early chemotherapy failure [3] - The successful development of this detection kit is expected to advance clinical trials and enhance precision diagnosis and treatment for lymphoma patients in China once approved by the National Medical Products Administration (NMPA) [3]